Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $12.50, for a total value of $25,000.00. Following the completion of the sale, the president now owns 2,924,467 shares of the company’s stock, valued at $36,555,837.50. The trade was a 0.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Songjiang Ma also recently made the following trade(s):

• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total value of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Down 0.8 %

Shares of GYRE opened at $12.00 on Friday. The company has a 50 day moving average price of $12.56 and a 200-day moving average price of $12.67. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $27.10.

Hedge Funds Weigh In On Gyre Therapeutics

A number of large investors have recently bought and sold shares of the business. Barclays PLC increased its holdings in shares of Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the period. Geode Capital Management LLC grew its stake in Gyre Therapeutics by 16.9% in the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares during the last quarter. State Street Corp raised its holdings in Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares in the last quarter. FMR LLC purchased a new stake in shares of Gyre Therapeutics during the third quarter valued at about $47,000. Finally, Advantage Alpha Capital Partners LP bought a new stake in shares of Gyre Therapeutics in the 3rd quarter valued at about $334,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.